Тардиферон (Ferrous Sulfate prolonged-release) is commonly used to treat and prevent health conditions associated with a mineral deficit: a shortage of iron. Its primary therapeutic role is to correct this underlying imbalance and contribute to functional stability. The medication is commonly used across conditions presenting with iron-deficiency anemia (IDA) and the earlier stage known as latent iron deficiency (depleted iron stores).

The medication is used for managing symptom clusters that interfere with daily functioning, specifically symptoms related to physical discomfort, such as fatigue and weakness. It is relevant for easing symptoms related to systemic imbalance, such as shortness of breath or a rapid heartbeat. This provides supportive relief when symptoms interfere with routine activities and helps maintain a sense of stability when symptoms are more noticeable. The iron preparation is relevant in contexts involving heightened systemic burden, including to prevent or treat iron deficiency during pregnancy and in cases of chronic iron loss due to heavy menstrual bleeding.

“The medication supports the body’s essential iron reserves and contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Symptomatic Support for Fatigue and Weakness

Focus	Details
Primary Indication	Iron-deficiency anemia (IDA) and latent iron deficiency.
Key Symptom Domain	Symptoms related to physical discomfort (e.g., fatigue, weakness).
Common Scenarios	Pregnancy (prophylactic/treatment) and chronic blood loss.
Patient Benefit	Assists with symptomatic relief and supports functional stability.

Eligibility Map: Who can and cannot use Тардиферон — official regulatory information

Tardiferron (Ferrous Iron as Ferrous sulphate dried) is generally for adults and is restricted in certain patient populations as defined in official regulatory documents.

---

Populations for Whom Use is Restricted or Prohibited

Classification	Population/Condition
Contraindicated	Hypersensitivity (allergy) to the active substance or excipients
Contraindicated	Conditions involving iron overload, such as haemochromatosis, refractory anaemia, thalassaemia, or aplastic anaemia
Not Recommended	Iron deficiency associated with inflammatory syndromes (as iron treatment is ineffective in this context)
Special Caution	Elderly patients and those with swallowing difficulties due to the high risk of serious esophageal or bronchial injury if the tablet is inhaled

---

Age-Related and Physiological Eligibility

• Pregnancy: Use is permitted for preventive treatment during the last two trimesters (from the 4th month onwards).
• Lactation: Use is generally permitted during breast-feeding.

To maintain eligibility and prevent injury, the tablets must not be sucked, chewed, or kept in the mouth but must be swallowed whole with water. This restriction is in place to avoid the risk of mouth ulcers and tooth discolouration. This medicine is intended for iron deficiency only, and its use is subject to ruling out conditions of iron overload.

Interactions with other medicines and products

Iron preparations, such as Tardiferon (Ferrous Sulfate), can significantly affect the absorption of other medications, and conversely, the absorption of iron can be reduced by certain co-administered substances. These pharmacokinetic interactions are primarily due to the formation of non-absorbable complexes in the digestive tract, resulting in lower effectiveness of one or both drugs.

Required Dose Separation

To manage these interactions, it is essential to stagger the administration of Tardiferon and the interacting medicines by several hours. This separation is typically classified as a use-with-caution or special precaution requirement by regulatory bodies.

Interacting Product Category	Potential Effect & Restriction
Tetracycline & Quinolone Antibiotics (e.g., Doxycycline, Ciprofloxacin)	Reduced absorption of the antibiotic. Requires strict spacing.
Thyroid Hormones (e.g., Levothyroxine)	Reduced absorption of the thyroid hormone. Separate doses by at least 2 to 4 hours.
Bisphosphonates, Penicillamine, Methyldopa	Reduced absorption of these drugs. Requires time separation.
Antacids (containing Calcium, Magnesium, Aluminum), Oral Calcium Salts	Reduced absorption of iron. Separate doses by at least 2 hours.

Other Notable Interactions

Concomitant use of Ascorbic Acid (Vitamin C) may increase the absorption of iron. Conversely, the absorption of iron is reduced when taken with Cholestyramine or certain mineral supplements containing Zinc or other ferrous salts. Patients should follow healthcare provider instructions regarding the precise timing of all medications.

The mechanism of Тардиферон (Ferrous Sulfate) is a fundamental process of elemental replacement, designed to restore the functional pools of iron required for key biological processes. It operates by providing the essential mineral substrate, ferrous iron ( Fe^2+), rather than modulating chemical signals like receptors or enzymes.

Restoring Elemental Uptake and Systemic Transport

The mechanism initiates in the small intestine, where the Fe^2+ ions are gradually released by the prolonged-release tablet. These ions are actively transported into the absorptive cells via the Divalent Metal Transporter 1 (DMT1) and released into the bloodstream by Ferroportin. Once in the plasma, the iron is immediately bound to the carrier protein, Transferrin, which enables systemic distribution to avoid toxicity from free iron. This transport mechanism delivers the essential substrate to all tissues, most critically the bone marrow.

Supporting Heme Synthesis and Oxygen Capacity

The main physiological consequence occurs in the bone marrow, where the transported iron acts as a core substrate to complete heme synthesis, which is then incorporated into the Hemoglobin molecule. By restoring this critical component, the drug facilitates the entire process of erythropoiesis (red blood cell production), leading to an increase in the blood's oxygen-carrying capacity. Iron is also essential for cytochrome enzymes, thereby contributing to cellular energy metabolism (ATP production).

How to Use Тардиферон: Administration Guidelines

Тардиферон is a prolonged-release, film-coated tablet for oral administration only. Guidelines focus on maintaining the tablet's integrity and optimizing iron absorption.

---

Standard Dosing and Duration

Purpose	Typical Adult Regimen	Duration
Treatment of Iron Deficiency Anemia	1 to 2 tablets per day (80 mg to 160 mg elemental iron).	Continue for 3 to 6 months after correction of iron levels to replenish body stores.
Iron Prophylaxis (e.g., in Pregnancy)	1 tablet (80 mg) every other day, typically starting from the second trimester.	Continues for the duration of the risk period.

---

Administration Requirements

Proper use of this prolonged-release formulation requires adherence to specific procedures:

• Method: The tablet must be swallowed whole with a glass of water. It must not be sucked, chewed, or kept in the mouth before swallowing. This action is critical for the intended gradual release of iron into the digestive tract.
• Timing: The dose is generally taken before or during meals, depending on individual tolerance. To prevent reduced absorption, the tablet should be taken with a 2-hour gap before or after consuming certain inhibitory substances, such as tea, coffee, dairy products, or whole grains.
• Population Rules: The tablet is indicated for use in children over 10 years of age at a dose similar to the adult regimen. Standard adult dosing applies to the elderly.

Тардиферон: Recent Clinical Evidence

Clinical research regarding oral iron supplementation, including prolonged-release ferrous sulfate (the active ingredient in Tardyferon), generally supports its use in addressing iron deficiency and iron deficiency anemia (IDA). Studies often focus on the extended-release formulation's pharmacokinetic properties and its application in populations with high iron requirements, such as pregnant women and women of childbearing age.

Pharmacokinetic Studies and Delivery Profile

Pharmacokinetic research has characterized the unique release profile of the prolonged-release formulation. One study in non-pregnant women with IDA demonstrated that a single oral dose resulted in elevated serum iron levels for up to 12 hours after administration. The concentration remained relatively stable between 2 and 8 hours post-dosing. This prolonged-release approach is theorized to potentially enhance iron absorption by allowing the iron to reach lower segments of the small intestine, which may reduce the incidence of certain gastrointestinal side effects commonly associated with immediate-release iron salts.

Focus Area	Key Observation (Studies Suggest)
Iron Absorption	Prolonged release profile maintains elevated iron levels for an extended period (up to 12 hours).
Tolerability	Modified release may be associated with a reduced incidence of overall and gastrointestinal adverse events, potentially supporting better adherence.

Role in Iron Deficiency Management

Oral ferrous sulfate is widely recognized in international guidelines as a standard option for preventing and treating iron deficiency, particularly during pregnancy. Meta-analyses of iron and folic acid supplementation (often combined, such as in Tardyferon-Fol) during pregnancy suggest an association with a reduced risk of maternal anemia at term. Observational studies in clinical practice also indicate that iron-based medication is frequently prescribed to manage the estimated risk of iron deficiency and the prevalence of anemia observed throughout pregnancy.

Research continues to evaluate optimal strategies for treating IDA. While newer intravenous (IV) iron formulations are being studied for moderate to severe cases, oral preparations like prolonged-release ferrous sulfate remain a primary approach for long-term iron repletion and management of deficiency.

Common questions about Тардиферон (FAQ)

Q: Are changes in stool color expected when taking Тардиферон?

Official regulatory information indicates that darkening of the stools is a very common and expected occurrence when taking this type of iron preparation. This is a normal result of the unabsorbed iron passing through the digestive system.

Q: Can I take Тардиферон on an empty stomach?

Official administration instructions state that the dose is generally taken before or during meals. Patients should follow the administration guidance provided by their healthcare professional regarding specific timing.

Q: Does the package insert mention any specific food to avoid with Тардиферон?

Official documentation describes a required 2-hour gap before or after consuming substances that may reduce iron absorption, such as tea, coffee, dairy products, or whole grains. This separation is advised to minimize the reduction in iron uptake.

Q: Are there warnings about taking it with antibiotics?

Regulatory sources list specific interactions with certain types of antibiotics, primarily tetracycline and quinolone antibiotics. These interactions may reduce the effectiveness of the antibiotic, making time separation an essential precaution described in official warnings.

Q: Can I drink coffee or tea when I am taking Тардиферон?

Official administration guidelines describe taking the tablet with a 2-hour gap from these beverages to minimize the reduction in iron absorption, as coffee and tea are known to inhibit iron uptake.

Q: Why do some people report constipation with iron supplements like Тардиферон?

Constipation is a common side effect of oral iron supplements. This medicine uses a prolonged-release system in its formulation, which studies suggest is associated with a reduced incidence of gastrointestinal adverse events compared to some immediate-release forms.

Q: Can I take other supplements (like zinc) while using Тардиферон?

Regulatory documents indicate that iron absorption may be reduced when taken at the same time as certain other mineral supplements. Specifically, supplements containing Zinc have been noted in the interaction information for iron preparations.

Q: Is it true that this iron is better tolerated than others?

Studies suggest the modified-release formulation may be associated with a reduced incidence of gastrointestinal adverse events. This observation is related to the gradual release of iron into the digestive system.

Q: Why is this drug called 'Tardiferon'?

The name is associated with the tablet's key design feature: the prolonged-release system. The 'Tardy' or 'Tardi' part of the name refers to the delayed or slow, controlled release of the iron component over time.

Q: How does the slow-release feature of Тардиферон work?

The tablet is formulated with a unique matrix that ensures a slow, consistent, and gradual release of the ferrous iron. This allows the iron to be absorbed over an extended period as it moves through the digestive tract.

Q: Is Тардиферон used only for anemia?

No. Official indications for the medicine include both the treatment of iron deficiency anemia and the prevention of iron deficiency (prophylaxis). Prophylaxis is often used in specific populations, such as during pregnancy.

Q: What is the difference between Тардиферон and other iron pills?

The primary distinction is the prolonged-release system of this product. This feature is an intentional design choice that separates it from standard, immediate-release iron salts used for oral supplementation.

Q: Is a prescription needed for Тардиферон?

The regulatory status of the medication can differ depending on the country or region. In some jurisdictions, this iron product may be classified and authorized for sale without a physician's prescription.

Q: What happens if I miss taking a dose?

Official guidance for iron preparations generally advises against taking a double dose to try and make up for a missed one. Patients should follow the guidance of their healthcare professional if a dose is missed.

Q: Is this medicine suitable for children?

The official product information indicates the tablet is suitable for use in children over 10 years of age at a dose similar to the adult regimen. Usage in younger children is not included in the standard indication.

Q: Does alcohol consumption affect the use of Тардиферон?

There is no specific warning about an interaction with alcohol listed in the drug's official regulatory documentation.

Q: Is Тардиферон used to treat general fatigue?

The medicine is officially indicated for addressing iron deficiency and iron deficiency anemia. While fatigue is a symptom often associated with this deficiency, the drug is intended to treat the underlying iron deficit.

Q: Is the iron content in the tablet considered high?

Official documentation states that each prolonged-release tablet provides 80 mg of elemental iron. This concentration is standard for treating and preventing iron deficiency.

Q: What should I do if I accidentally take too many tablets?

Regulatory safety information highlights the critical concern of accidental fatal overdose with iron products, particularly in children. Guidelines provide general information on the description and management of an overdose.

Q: What kind of studies support the use of this drug?

Clinical evidence for this medicine includes studies that focus on its pharmacokinetic properties and its modified-release delivery profile. Other supporting research, such as meta-analyses, validates the overall use of oral ferrous sulfate for managing iron deficiency.

Q: Why is iron deficiency common in certain groups of people?

Official guidance often highlights specific patient groups in the dosing instructions due to their increased iron requirements. These groups include pregnant women and women of childbearing age, who are frequently at higher risk for deficiency.

Q: Is it safe to discontinue the use of this drug suddenly?

Official guidelines state that treatment for iron deficiency anemia should continue for 3 to 6 months after the correction of iron levels. Treatment guidelines often recommend an extended duration to support the full replenishment of the body’s iron stores.

Q: Do regulatory bodies approve the use of Тардиферон for prophylactic purposes?

Yes, regulatory indications specifically include the prevention of iron deficiency (prophylaxis). A recognized example of this use is preventive treatment in pregnant women, typically starting from the second trimester.

Q: What is the difference between the 80 mg and 50 mg versions, if they exist?

Different formulations may be available based on regional markets. The 80 mg version is a ferrous sulfate tablet, while a 50 mg version is frequently a combination product that includes an additional substance like folic acid (Vitamin B9).

Q: Can stomach acid levels affect how well Тардиферон works?

The drug’s mechanism of action involves the release of ferrous iron and its subsequent uptake in the small intestine. This absorption process is known to be influenced by the digestive environment, including factors like stomach acid levels.

How to Store and Dispose of Tardyferon

Tardyferon (Ferrous Sulfate prolonged-release tablets) must be stored and disposed of according to official regulatory instructions to ensure product stability and safety.

Storage Conditions

Requirement	Regulatory Standard
Temperature	Store below 25 C (or 30 C, depending on region).
Protection	Protect the tablets from moisture and store in the original packaging.
Child Safety	Keep out of the sight and reach of children due to the high risk of iron poisoning.

Disposal Instructions

Unused or expired Tardyferon must not be disposed of using household waste or wastewater. Discarding the product must follow local requirements for pharmaceutical waste, often through a pharmacy take-back program. This procedure is mandated to prevent environmental contamination and accidental exposure.